Skip to main content

Advertisement

Table 2 Correlation between PIM-1 expression and clinicopathological features in patients with acute myeloid leukemia (AML)

From: PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia

Clinicopathological feature Total mRNA expression of PIM-1 P value
Low (n = 38, 32.2%) High (n = 80, 67.8%)
Gender
 Male 62 17 (27.5%) 45 (72.5%) 0.1522
 Female 56 21 (37.5%) 35 (62.5%)
Age (years)
 ≤47 67 21 (31.3%) 46 (68.7%) 0.3469
 >47 51 17 (33.3%) 34 (66.7%)
WBC (×109)
 <10 57 16 (28.1%) 41 (71.9%) 0.9206
 >10 61 22 (36.1%) 39 (63.9%)
Hb (g/L)
 <81 66 18 (27.3%) 48 (72.7%) 0.7689
 >81 52 20 (38.5%) 32 (61.5%)
PLT (×109)
 <57 75 28 (37.3%) 47 (62.7%) 0.7321
 >57 43 10 (23.3%) 33 (76.7%)
Blasts (%)
 <62 54 14 (25.9%) 40 (74.1%) 0.1762
 >62 64 24 (37.5%) 40 (62.5%)
FAB classification
 M1 4 1 (25%) 3 (75%) 0.1162
 M2 35 15 (42.9%) 20 (57.1%)
 M4 37 11 (29.7%) 26 (70.3%)
 M5 37 9 (24.3%) 28 (75.7%)
 M6 5 2 (40%) 3 (60%)
Risk stratification
 Low risk 49 24 (48.9%) 25 (51.1%) 0.0029a
 Intermediate risk 28 9 (32.1%) 19 (67.2%)
 High risk 41 5 (12.2%) 36 (87.8%)
Treatment
 Chemotherapy 87 26 (29.9%) 61 (70.1%) 0.9098
 HSCT 31 12 (38.7%) 19 (61.3%)
Vital status
 Survival 27 14 (51.9%) 13 (48.1%) 0.0322a
 Death 91 24 (26.4%) 67 (73.6%)
  1. HSCT hematopoietic stem cell transplant
  2. aStatistically significant